Circulating levels of cell adhesion molecule l1 as a prognostic marker in gastrointestinal stromal tumor patients

Hilke Zander, Tamina Rawnaq, Max von Wedemeyer, Michael Tachezy, Miriam Kunkel, Gerrit Wolters, Maximilian Bockhorn, Melitta Schachner, Jakob R. Izbicki, Jussuf Kaifi

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Background: L1 cell adhesion molecule (CD171) is expressed in many malignant tumors and its expression correlates with unfavourable outcome. It thus represents a target for tumor diagnosis and therapy. An earlier study conducted by our group identified L1 expression levels in primary gastrointestinal stromal tumors (GIST) as a prognostic marker. The aim of the current study was to compare L1 serum levels of GIST patients with those of healthy controls and to determine whether levels of soluble L1 in sera could serve as a prognostic marker.Methods: Using a sensitive enzyme-linked immunosorbent assay (ELISA), soluble L1 was measured in sera of 93 GIST patients und 151 healthy controls. Soluble L1 levels were then correlated with clinicopathological data.Results: Median levels of soluble L1 were significantly higher (p < 0.001; Mann-Whitney U test) in sera of GIST patients compared to healthy individuals. Median soluble L1 levels were particularly elevated in patients with recurrence and relapse (p < 0.05; Mann Whitney U test).Conclusion: These results suggest that high soluble L1 levels predict poor prognosis and may thus be a promising tumor marker that can contribute to individualise therapy.

Original languageEnglish (US)
Article number189
JournalBMC cancer
StatePublished - May 22 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research


  • Enzyme-linked Immunosorbent assay (ELISA)
  • Gastrointestinal stromal tumor (GIST)
  • L1
  • Progression marker


Dive into the research topics of 'Circulating levels of cell adhesion molecule l1 as a prognostic marker in gastrointestinal stromal tumor patients'. Together they form a unique fingerprint.

Cite this